Bio-Techne (NASDAQ: TECH) exec updates option and RSU holdings
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reports that officer William Geist had several equity award updates on 8/15/2026. He acquired 6,416 shares of common stock through the vesting and conversion of restricted stock units and performance RSUs/options, while 1,976 shares of common stock were delivered or withheld at $72.40 per share to cover exercise price or tax liability. The Board authorized discretionary vesting of 567 performance RSUs and 1,526 performance options, with the remaining performance RSUs and options from those grants forfeited and reported as dispositions to the issuer. Geist continues to hold multiple option grants and performance RSUs with future vesting and performance-based vesting dates out to 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,440 shares
Net Buy
14 txns
Insider
Geist William
Role
PRESIDENT, PROTEIN SCIENCES
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Restricted Stock Units F1, F3 | 567 | $0.00 | $0.00 |
| Disposition | Performance Restricted Stock Units F1, F3 | 8,507 | $0.00 | $0.00 |
| Disposition | Performance Stock Options (Right to Buy) F5 | 22,898 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F7 | 2,623 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F1, F10 | 3,226 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,416 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,976 | $72.40 | $143K |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Performance Restricted Stock Units F1, F6 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F8 | -- | -- | -- |
| holding | Performance Restricted Stock Units F1, F9 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F11 | -- | -- | -- |
Holdings After Transaction:
Performance Restricted Stock Units — 35,093 shares (Direct);
Performance Stock Options (Right to Buy) — 1,526 shares (Direct);
Restricted Stock Units — 9,075 shares (Direct);
Common Stock — 24,943 shares (Direct);
Stock Options (Right to Buy) — 121,533 shares (Direct)
Footnotes (11)
- F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2. 100% vested.
- F3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited.
- F4. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
- F5. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited.
- F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7. 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F8. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F10. 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F11. Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.
Key Figures
Shares acquired via RSU/PSU vesting: 6,416 shares
Shares withheld for exercise price or tax liability: 1,976 shares at $72.40 per share
Performance RSUs vested: 567 units
+5 more
8 metrics
Shares acquired via RSU/PSU vesting
6,416 shares
Common stock acquired on 8/15/2026 through conversion of restricted and performance units/options
Shares withheld for exercise price or tax liability
1,976 shares at $72.40 per share
Common stock delivered/withheld on 8/15/2026 to cover award-related costs
Performance RSUs vested
567 units
Discretionary vesting authorized by the Board on 8/15/2026
Performance options forfeited
22,898 options at $84.61
Options disposed to issuer on 8/15/2026; 1,526 options from the grant were vested
Remaining options at $94.52
29,600 underlying shares
Stock options (right to buy) expiring 8/15/2029, held directly
Remaining options at $84.61
30,059 underlying shares
Stock options (right to buy) expiring 8/15/2030, held directly
Remaining options at $53.60
24,758 underlying shares
Stock options (right to buy) expiring 8/15/2035, held directly
Remaining performance RSUs block
19,355 underlying shares
Performance restricted stock units vesting based on goals by 8/15/2028 or later certification
Key Terms
Performance Restricted Stock Units, Restricted Stock Units, Stock Options (Right to Buy), exercise price, +1 more
5 terms
Performance Restricted Stock Units financial
"Performance Restricted Stock Units vest based on achievement of performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with specified exercise prices and expiration dates"
exercise price financial
"Stock options carry an exercise price such as $84.61 or $53.60 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Options and RSUs vest on specific dates or upon achievement of performance goals"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did BIO-TECHNE (TECH) executive William Geist have vest on 8/15/2026?
On 8/15/2026, William Geist had restricted stock units and performance-based RSUs/options vest into 6,416 shares of common stock. These awards reflect previously granted equity incentives converting into actual BIO-TECHNE shares.
What happened to William Geist’s performance RSUs at BIO-TECHNE (TECH)?
The Board authorized discretionary vesting of 567 performance RSUs for William Geist on 8/15/2026. The filing states that the remainder of his performance RSUs from that grant were forfeited and reported as a disposition to the issuer.
What changes occurred to William Geist’s performance stock options at BIO-TECHNE (TECH)?
On 8/15/2026, the Board authorized discretionary vesting of 1,526 performance options for Geist. The remaining performance options from that grant were forfeited, with 22,898 options reported as a disposition to the issuer at a strike price of $84.61.
What stock option holdings does William Geist retain in BIO-TECHNE (TECH) after these transactions?
Geist retains several option grants on BIO-TECHNE common stock, including options over 29,600 shares at $94.52 expiring 8/15/2029 and 30,059 shares at $84.61 expiring 8/15/2030, plus additional grants with later expirations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
